Skip to main content
Premium Trial:

Request an Annual Quote

Avacta Anti di-Ubiquitin K6 and K33 Affimers

Avacta has released Anti di-Ubiquitin K6 and K33 Affimers. Affimer binders are produced entirely in vitro and are therefore not restricted by the host immune system. The technology is suited for difficult targets such as K6 and K33, the exact function of which is largely unknown due to the limited tools available. The Anti di-Ubiquitin Affimer range is human-specific and includes a variety of tagged binders displaying high affinities for poly-ubiquitin chains formed by K6 or K33 linkages, in protein expression studies.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.